Gleevec Buoyed By GIST Trial Results; Novartis Will Seek Adjuvant Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
NCI-sponsored study halted after imatinib meets primary endpoint, rate of recurrence-free survival, in Kit-positive GIST patients.
You may also be interested in...
FDA Cites Gleevec For Promoting Unapproved Indications Three Weeks Before Expanding Label
Notice of violation letter to Novartis from FDA’s Office of Prescription Drug Promotion expresses concern about describing a patient with five-year survival data, a claim that was added to the label the following month.
Gleevec Extends Post-Surgery GIST Survival Significantly; Wins Full Adjuvant Approval
Patients who took Novartis’ Gleevec for three years after surgery to remove gastrointestinal stromal tumors had a 54% reduction in risk of recurrence and a 55% reduction in risk of death compared to patients who took it for only one year.
Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Novartis’ oncology chief discusses in-licensing candidates, as well as how biologics fit into the firm’s oncology pipeline.